This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health (CAH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Fresenius Medical (FMS) Divests Assets to Optimize Portfolio
by Zacks Equity Research
Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.
Zimmer Biomet (ZBH) Rides on ROSA Uptake, Favorable Trend
by Zacks Equity Research
Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Universal Health (UHS) Q4 Earnings Beat on Adjusted Admissions
by Zacks Equity Research
Universal Health (UHS) expects net revenues between $15.411 billion and $15.706 billion for 2024, which indicates 8.9% year-over-year growth.
Select Medical (SEM) Q4 Earnings Beat on Patient Admissions
by Zacks Equity Research
Select Medical's (SEM) Q4 results reflect strong segmental contribution, aided by higher patient days and visits. Management expects 2024 adjusted EBITDA to be $830-$880 million, up from the 2023 reported figure of $807.4 million.
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.
Zimmer (ZBH) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 2.33% and 0.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Curious about Zimmer (ZBH) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
3 Reasons to Hold Zimmer Biomet (ZBH) Stock in Your Portfolio
by Zacks Equity Research
Zimmer Biomet's (ZBH) focus on emerging markets raises optimism about the stock.
Why Is Zimmer (ZBH) Up 10.8% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH), driven by a recovery in business and an expanding global footprint.
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt
by Zacks Equity Research
Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 3.77% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Zimmer Biomet (ZBH) Might Surprise This Earnings Season
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stay Ahead of the Game With Zimmer (ZBH) Q3 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.